The study of terminated PEG maleimide synthesis and modification of hemoglobin

DOI

10.2991/emeit.2012.222How to use a DOI?

Keywords

PEGylation, hemoglobin (Hb), mPEG-MAL, Blood substitute, modify

Abstract

There is a worldwide increased demand for blood transfusions. In Third World countries is not sufficient due to the spreading of infections, such as HIV. The current generation of so-called hemoglobin-based oxygen carriers (HBOCs) comprise hemoglobins from different species (human and bovine) that have been chemically modified to improve structural stability. However, some adverse effects such as hypertension, myocardial infarction and acute kidney failure have been found in several clinical trials. The exact factors leading to the symptoms are still uncertain, but high molecular weight was believed to play an important role. Therefore, Maleimide polyethylene glycol 5000 monomethyl ether(mPEG-MAL) as Hemoglobin(Hb) modifier can change the Molecular weight of Human placenta hemoglobin effectively. In addition, hemoglobin weight could be severely controlled by changing the amount of the sulfhydryl modifier and mPEG-MAL, so as to achieve the demand of the people of different molecular weight.

Copyright

© 2012, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Lei Zhang
AU  - Xiang Wang
AU  - Donglai Qi
PY  - 2012/09
DA  - 2012/09
TI  - The study of terminated PEG maleimide synthesis and modification of hemoglobin
BT  - Proceedings of the 2nd International Conference on Electronic & Mechanical Engineering and Information Technology (EMEIT 2012)
PB  - Atlantis Press
SP  - 1022
EP  - 1025
SN  - 1951-6851
UR  - https://doi.org/10.2991/emeit.2012.222
DO  - 10.2991/emeit.2012.222
ID  - Zhang2012/09
ER  -